 OyaGen is researching several compounds that prevent ViF from disabling A3G, including A3G agonists, ViF destabilizers and ViF dimerization antagonists.The company received seed funding from Trillium Group's University Technology Fund and the University of Rochester Medical Center.It has also received funding from the New York State Retirement Common Fund's Private Equity Program.